Positive Press Coverage Somewhat Unlikely to Affect Integra Lifesciences (IART) Stock Price

News coverage about Integra Lifesciences (NASDAQ:IART) has trended positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Integra Lifesciences earned a news impact score of 0.26 on Accern’s scale. Accern also gave news headlines about the life sciences company an impact score of 46.395314194992 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Integra Lifesciences (IART) opened at $49.99 on Thursday. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26. Integra Lifesciences has a fifty-two week low of $40.51 and a fifty-two week high of $56.42. The stock has a market cap of $3,920.00, a P/E ratio of 81.95, a price-to-earnings-growth ratio of 1.63 and a beta of 0.65.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The firm had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. During the same quarter in the previous year, the business posted $0.93 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. sell-side analysts forecast that Integra Lifesciences will post 1.85 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. Oppenheimer set a $58.00 price objective on shares of Integra Lifesciences and gave the company a “buy” rating in a report on Tuesday, December 12th. UBS Group reiterated a “buy” rating and issued a $57.00 price objective on shares of Integra Lifesciences in a report on Tuesday, October 31st. Jefferies Group reiterated a “buy” rating and issued a $58.00 price objective on shares of Integra Lifesciences in a report on Thursday, October 12th. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Tuesday, October 10th. Finally, TheStreet lowered shares of Integra Lifesciences from a “b” rating to a “c+” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $52.70.

In other news, Director Barbara B. Hill purchased 10,768 shares of the stock in a transaction on Tuesday, October 31st. The stock was purchased at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the acquisition, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. 21.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/18/positive-press-coverage-somewhat-unlikely-to-affect-integra-lifesciences-iart-stock-price.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply